Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International Collaborative Gaucher Group (ICGG) Gaucher Registry

Trial Profile

International Collaborative Gaucher Group (ICGG) Gaucher Registry

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alglucerase (Primary) ; Imiglucerase (Primary)
  • Indications Gaucher's disease; Gaucher's disease type I
  • Focus Therapeutic Use
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 07 Jun 2019 Planned End Date changed from 31 Jan 2030 to 31 Jan 2034.
    • 07 Jun 2019 Planned primary completion date changed from 31 Jan 2030 to 31 Jan 2034.
    • 01 Sep 2017 Results (Data cut off 4 March 2016; n=2069) of an analysis assessing prevalence of severe clinical manifestations in Gaucher disease type 1 (GD1) patients at the time of treatment initiation since alglucerase/imiglucerase approval in USA, published in the American Journal of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top